Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.
You may also be interested in...
Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.
Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research
Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.
Alzheimer’s Biomarkers For Disease Progression Will Be A Hard Road, Experts Say
A panel of experts discussing challenges in researching disease-progression biomarkers for Alzheimer’s agreed that the heterogeneity and evolving nature of the disease complicate the task and may require large panels of biomarkers – a potentially costly and invasive solution.